Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
2024年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "海思科医药集团股份有限公司2024 年半年度报告全文" which translates to "Haisco Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company overview, business segments, R&D progress, sales and production data, and future plans. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial figures for the half-year period 2024, management commentary, and detailed operational data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. There is no indication that this is merely an announcement or a certification, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-15 Chinese
2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 半年度募集资金存放与实际使用情况的专项报告" which translates to "2024 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their usage, storage, management, and compliance with regulatory requirements. The document includes detailed financial figures related to fundraising activities, usage of funds, and cash management. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes auditor verification reports. The document is a comprehensive report on the use of capital raised by the company during a half-year period, focusing on fundraising and capital usage rather than general financial performance or earnings. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (9296 characters) and detailed content confirm it is a report, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2024-08-15 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 海思科医药集团股份有限公司, detailing decisions made at the fifth board's seventeenth meeting held on August 15, 2024. It includes approvals of the 2024 semi-annual report and summary, amendments to the company charter, profit distribution proposals, and adjustments to subsidiary shareholding structures. The document references other announcements and reports published elsewhere but does not contain the full semi-annual report or detailed financial statements itself. The document is relatively short (1541 characters) and serves as an official announcement of board resolutions rather than the full report or detailed financial data. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-08-15 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the first half of 2024 by the company 海思科医药集团股份有限公司. It includes specific financial figures for the period, such as beginning balances, cumulative amounts, interest, repayments, and ending balances. The document is relatively short (1367 characters) and appears to be a detailed financial disclosure related to related-party transactions and fund usage rather than a full financial report. It does not contain comprehensive financial statements or management discussion but is a specific financial disclosure likely required by regulatory authorities. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories like Annual Report or Interim Report. Therefore, the classification is RNS with high confidence.
2024-08-15 Chinese
2024年限制性股票激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of a 2024 restricted stock incentive plan for Haishike Pharmaceutical Group Co., Ltd. It includes legal references, plan purpose, management structure, scope of incentive recipients, stock grant details, pricing, vesting conditions, performance targets, accounting treatment, and procedures for implementation and adjustments. The content is focused on the company's stock incentive plan, which is a form of equity compensation for employees and management. This type of document is typically classified under Capital/Financing Update (CAP) because it relates to changes in the company's capital structure and financing arrangements through stock incentives. It is not an announcement of a report, nor a full annual or interim report, nor a regulatory filing or governance document. Therefore, the appropriate classification is CAP with high confidence.
2024-08-14 Chinese
2024年股权激励计划草案自查表
Board/Management Information Classification · 95% confidence The document is a detailed compliance self-checklist related to a 2024 equity incentive plan draft for a listed company, 海思科医药集团股份有限公司. It includes numerous compliance and regulatory checks, references to legal and regulatory requirements, and internal governance procedures related to the equity incentive plan. There are no financial statements, earnings data, or audit opinions presented as standalone reports. The document is not an announcement of a report but a compliance checklist and internal governance document related to management and board-level decisions on equity incentives. This fits best under Board/Management Information (MANG), as it relates to management and board-level compliance and governance regarding equity incentive plans.
2024-08-14 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.